D. Porter

Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis

T. Alcindor, M. Shapiro, F. Foss, 2002, Bone Marrow Transplantation.

Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance

J. McQuade, D. Porter, S. Schuster, 2012, Bone Marrow Transplantation.

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

C. Hardy, D. Porter, H. Moore, 1999, Bone Marrow Transplantation.

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

A. Gewirtz, S. Luger, E. Stadtmauer, 2002, Bone Marrow Transplantation.

Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.

U. Jäger, R. Maziarz, M. Ruella, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES

C. June, S. Schuster, D. Porter, 2019, Hematological Oncology.

Gut Associated Lymphoid Tissue (GALT) primary cells and stable cell lines as predictive models for intestinal health in rainbow trout (Oncorhynchus mykiss)

D. Peggs, D. Porter, S. Martin, 2022, Frontiers in Immunology.